Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.

Hippocampal GABA helps suppress unwanted thoughts

10 Nov 2017
Depression has become the leading cause of morbidity and disability in the world.

Inhibition of hippocampal retrieval processes through gamma-aminobutyric acid (GABA) enables the suppression of intrusive thoughts, a recent study shows.

Thirty right-handed participants (mean age 24.7±4.3 years; males n=7) were subjected to two behavioural tasks. The first was a stop signal (SS) task, where participants were made to press a specific button in response to a coloured circle stimulus flashed on-screen. If the stimulus came with a beeping sound, participants were asked to prevent their response.

The second was a Think/No-Think (TNT) task, where they were shown reminders of unwanted thoughts and instructed to suppress retrieval. Functional magnetic resonance imaging (fMRI) was performed during each task and 1H magnetic resonance spectroscopy (1H-MRS) was used to measure GABA.

The researchers found that No-Think trial elicited significantly reduced activity both in right (p=0.003) and left (p=0.001) hippocampus. Retrieval suppression also resulted in impaired memory of the items, with No-Think items being recalled significantly less in a postscan recall test than the Think items (59±3 vs 65±3 percent; p=0.04).

Moreover, hippocampal GABA showed a significantly negative correlation with hippocampal blood-oxygen level-dependent activity signals during Think and No-Think (p<0.05 for both) conditions but not during Go or Stop conditions.

Finally, those with higher hippocampal GABA also showed stronger negative coupling between the hippocampus and dorsolateral prefrontal cortex, while those with lower hippocampal GABA did not show this negative coupling during retrieval suppression. The difference in connectivity between the two groups reached statistical significance (p=0.03).

“The present findings raise the possibility that GABAergic disinhibition in the hippocampus contributes to reduced fronto-hippocampal connectivity, hippocampal hyperactivity and intrusive symptomatology,” researchers said.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.